Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Fig. 1

Day 85 trough FEV1 by patient subgroup. The LS mean difference for revefenacin versus placebo was statistically significant (p < 0.05) for all subgroups. CI confidence intervals; CV cardiovascular; FEV1 forced expiratory volume in 1 s; GOLD Global Initiative for Chronic Obstructive Lung Disease; LABA long-acting ß agonist; ICS inhaled corticosteroids; ITT intention-to-treat

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us